↓ Skip to main content

Marine ω-3 polyunsaturated fatty acid and fish intake after colon cancer diagnosis and survival: CALGB 89803 (Alliance)

Overview of attention for article published in Cancer Epidemiology, Biomarkers & Prevention, April 2018
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (81st percentile)
  • High Attention Score compared to outputs of the same age and source (80th percentile)

Mentioned by

news
1 news outlet
twitter
5 X users

Citations

dimensions_citation
53 Dimensions

Readers on

mendeley
76 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Marine ω-3 polyunsaturated fatty acid and fish intake after colon cancer diagnosis and survival: CALGB 89803 (Alliance)
Published in
Cancer Epidemiology, Biomarkers & Prevention, April 2018
DOI 10.1158/1055-9965.epi-17-0689
Pubmed ID
Authors

Erin L Van Blarigan, Charles S Fuchs, Donna Niedzwiecki, Xing Ye, Sui Zhang, Mingyang Song, Leonard B Saltz, Robert J Mayer, Rex B Mowat, Renaud Whittom, Alexander Hantel, Al Benson, Daniel Atienza, Michael Messino, Hedy Kindler, Alan Venook, Shuji Ogino, Edward L Giovannucci, Jeffrey A Meyerhardt

Abstract

Marine ω-3 polyunsaturated fatty acids (PUFAs), primarily found in dark fish, may prevent colorectal cancer progression, in part through inhibition of prostaglandin-endoperoxide synthase 2 (PTGS2). However, data in humans are limited. We examined marine ω-3 PUFAs and fish intake and survival among 1,011 colon cancer patients enrolled in CALGB 89803 between 1999 to 2001 and followed through 2009. Diet was assessed during and 6 months after chemotherapy. We used Cox proportional hazards regression to estimate hazard ratios (HR) and 95% confidence intervals (CI) for disease-free (DFS), recurrence-free (RFS), and overall survival (OS). We observed 343 recurrences and 305 deaths (median follow-up: 7 y). Patients in the highest vs. lowest quartile of marine ω-3 PUFA intake had a HR for DFS of 0.72 (95% CI: 0.54, 0.97; p-trend: 0.03). Individuals who consumed dark fish ≥1/week vs. never had longer DFS [HR: 0.65 (0.48, 0.87); p-value: 0.007], RFS [HR: 0.61 (0.46, 0.86); p-trend: 0.007], and OS [HR: 0.68 (0.48, 0.96); p-trend: 0.04]. In a subset of 510 patients, the association between marine ω-3 PUFA intake and DFS appeared stronger in patients with high PTGS2 expression [HR: 0.32 (0.11, 0.95); p-trend: 0.01] compared to patients with absent/low PTGS2 expression [HR: 0.78 (0.48, 1.27); p-trend: 0.35] (p-interaction: 0.19). Patients with high intake of marine ω-3 PUFAs and dark fish after colon cancer diagnosis may have longer DFS. Randomized controlled trials examining dark fish and/or marine ω-3 PUFA supplements and colon cancer recurrence/survival are needed.

X Demographics

X Demographics

The data shown below were collected from the profiles of 5 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 76 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 76 100%

Demographic breakdown

Readers by professional status Count As %
Student > Master 10 13%
Researcher 8 11%
Other 6 8%
Student > Bachelor 6 8%
Librarian 3 4%
Other 15 20%
Unknown 28 37%
Readers by discipline Count As %
Medicine and Dentistry 16 21%
Nursing and Health Professions 7 9%
Biochemistry, Genetics and Molecular Biology 4 5%
Immunology and Microbiology 3 4%
Engineering 2 3%
Other 5 7%
Unknown 39 51%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 12. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 17 June 2021.
All research outputs
#3,082,050
of 25,382,440 outputs
Outputs from Cancer Epidemiology, Biomarkers & Prevention
#883
of 4,849 outputs
Outputs of similar age
#61,509
of 342,742 outputs
Outputs of similar age from Cancer Epidemiology, Biomarkers & Prevention
#13
of 65 outputs
Altmetric has tracked 25,382,440 research outputs across all sources so far. Compared to these this one has done well and is in the 87th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 4,849 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 16.4. This one has done well, scoring higher than 81% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 342,742 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 81% of its contemporaries.
We're also able to compare this research output to 65 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 80% of its contemporaries.